Email Alert RSS
Volume 14 Issue 5
Sep.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
Citation: ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
shu

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-021

Beijing Municipal Commission of Sciences and Technology Z211100002921016

Dongcheng District Outstanding Talent Nurturing Program 2022-dchrcpyzz-69

More Information
  • Corresponding author:

    LI Jian, E-mail: lijian@pumch.cn

  • Received Date: May 07, 2023
  • Accepted Date: June 25, 2023
  • Available Online: July 12, 2023
  • Issue Publish Date: September 29, 2023
    Graphical Abstract
    • Abstract
  • Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by symptomatic inflammatory symptoms with poor prognosis. Interleukin-6 (IL-6) targeted therapy (eg. siltuximab) is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus. On July 2022, siltuximab became available in Chinese market, heralding the era of IL-6 targeted therapy in China. Thus, it is a good time point to review the state-of-the-art technology in the field of diagnosis and treatment of CD. We also highlight some of the clinical investigations conducted by Chinese researchers.
    • FullText(HTML)
    • References (13)
  • [1]
    Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9: 822-830. DOI: 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
    [2]
    Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. DOI: 10.1016/j.lanwpc.2023.100720
    [3]
    van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132: 2115-2124.
    [4]
    Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129: 1646-1657. DOI: 10.1182/blood-2016-10-746933
    [5]
    中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42: 529-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK202107001.htm
    [6]
    Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5: 122-128. DOI: 10.1182/bloodadvances.2020003607
    [7]
    Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol, 2018, 97: 1641-1647. DOI: 10.1007/s00277-018-3347-0
    [8]
    Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133: 1720-1728. DOI: 10.1182/blood-2018-11-884577
    [9]
    Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33: 1035-1038. DOI: 10.1038/s41375-018-0323-6
    [10]
    Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study[J]. Oncologist, 2020, 25: 963-973. DOI: 10.1634/theoncologist.2019-0986
    [11]
    Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation[J]. Chest, 2023. doi: 10.1016/j.chest.2023.03.022.
    [12]
    Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141: 2654-2657.
    [13]
    Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34: 100747. DOI: 10.1016/j.lanwpc.2023.100747
    • Related Articles

  • Related Articles

    [2]LIU Jingjing, WANG Xiaoting, LIU Dawei, CHAI Wenzhao. Cognitive Advances of Hospital Acquired Infection Prevention in the Department of Critical Care Medicine[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 479-482. DOI: 10.12290/xhyxzz.2024-0114
    [3]TANG Bo, CUI Na, HU Xiaoyun, LONG Yun, DU Bin. Comparison and Reflection on the Training System of Foreign Critical Care Medicine Specialists[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1105-1109. DOI: 10.12290/xhyxzz.2022-0125
    [4]GAO Chuan, ZHOU Yuyu, GUO Xufang, HE Zhong. Medical Humanities: the Past, Present and Future[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 152-157. DOI: 10.12290/xhyxzz.2021-0319
    [9]Xiang ZHOU, Da-wei LIU, Yun LONG, Bo YAO, Long-xiang SU. Risk Factors Related to Outcome of Patients with Severe Massive Hemorrhage in Intensive Care Unit[J]. Medical Journal of Peking Union Medical College Hospital, 2016, 7(5): 371-378. DOI: 10.3969/j.issn.1674-9081.2016.05.010

  • Cited by

    Periodical cited type(5)

    1. 王远，裴方，万丰，王泽宣，刘晓垒，郭开今. 人工全髋关节置换术中采用联合前倾角技术治疗强直性脊柱炎累及髋关节的疗效观察. 中国修复重建外科杂志. 2024(01): 15-21 .
    2. 孔德付，高延征，余正红，母心灵. 髋关节置换术对髋关节强直伴脊柱后凸患者脊柱-骨盆矢状位平衡的影响. 中华实用诊断与治疗杂志. 2024(09): 894-898 .
    3. 熊春翔，卫小春，尹东，黄宇，杜畅，莫冰峰. 强直性脊柱炎早发髋关节强直与HLA-B27基因亚型的易感性研究. 中国组织工程研究. 2019(23): 3710-3715 .
    4. 王河. 探讨全髋关节置换术在强直性脊柱炎中的应用进展. 四川解剖学杂志. 2019(03): 190-191 .
    5. 吴文锐，罗斯敏，刘宁，查振刚. 全髋关节置换术对强直性脊柱炎髋关节病变患者工作能力及功能恢复的影响. 南方医科大学学报. 2018(07): 879-883 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (397) PDF downloads (85) Cited by(8)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close